|
Sep 27
|
Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress
|
|
Sep 10
|
New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Jul 25
|
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
|
|
Jun 21
|
Sector Update: Health Care Stocks Gain in Late Afternoon
|
|
Jun 21
|
Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes
|
|
Jun 18
|
Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology
|
|
Jun 14
|
Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association
|
|
Jun 14
|
Tango Therapeutics (TNGX) Moves 10.3% Higher: Will This Strength Last?
|
|
May 30
|
Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial
|
|
May 14
|
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
|
|
May 9
|
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
|
|
May 6
|
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
|
|
May 3
|
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 2
|
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 2
|
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
|
|
May 2
|
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 29
|
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
|
|
Apr 29
|
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
|